University of Louisville

ThinkIR: The University of Louisville's Institutional Repository
Electronic Theses and Dissertations
12-2021

Computational modeling of 3D-printed Lactobacillus-antibiotic
scaffolds for bacterial vaginosis.
Veeresh P. Rai
University of Louisville

Follow this and additional works at: https://ir.library.louisville.edu/etd
Part of the Biomedical Engineering and Bioengineering Commons

Recommended Citation
Rai, Veeresh P., "Computational modeling of 3D-printed Lactobacillus-antibiotic scaffolds for bacterial
vaginosis." (2021). Electronic Theses and Dissertations. Paper 3917.
https://doi.org/10.18297/etd/3917

This Master's Thesis is brought to you for free and open access by ThinkIR: The University of Louisville's
Institutional Repository. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized
administrator of ThinkIR: The University of Louisville's Institutional Repository. This title appears here courtesy of
the author, who has retained all other copyrights. For more information, please contact thinkir@louisville.edu.

COMPUTATIONAL MODELING OF 3D-PRINTED, LACTOBACILLUS-ANTIBIOTIC
SCAFFOLDS FOR BACTERIAL VAGINOSIS

By
Veeresh P. Rai
B.S., University of Louisville, 2020

A Thesis
Submitted to the Faculty of the
University of Louisville
J.B. Speed School of Engineering
as Partial Fulfillment of the Requirements
for the Professional Degree

MASTER OF ENGINEERING

Department of Bioengineering

December 2021

COMPUTATIONAL MODELING OF 3D-PRINTED LACTOBACILLUS CRISPATUSANTIBIOTIC SCAFFOLDS IN THE FEMALE REPRODUCTIVE TRACT

Submitted by:__________________________________
Veeresh P. Rai

A Thesis Approved On

12/1/2021
__________________________________
(Date)

by the Following Reading and Examination Committee
___________________________________
Dr. Hermann B. Frieboes, Thesis Director

___________________________________
Dr. Jill M. Steinbach-Rankins

___________________________________
Dr. Nihat Altiparmak

ii

ACKNOWLEDGEMENTS
This project was made possible by the guidance of my thesis mentor, Dr. Hermann B.
Frieboes. Additionally, the insights of the members of the Reading and Examination
Committee, Dr. Jill M. Steinbach-Rankins and Dr. Nihat Altiparmak, were instrumental.
An additional acknowledgement for Michael Halwes and Dylan Goodin, the first of
which provided the foundational model for this project and the second of which whose
aid was very beneficial to the overall success of the project.

iii

ABSTRACT
The standard treatment for bacterial vaginosis (BV) is currently antibiotics, such as
metronidazole, clindamycin, or tinidazole. These antibiotics are highly effective in
getting rid of bacteria in the female reproductive tract (FRT); however, there are some
bacteria that provide benefits to the FRT which also get expunged. While there are many
strains of bacteria that play a beneficial role in the FRT, lactobacilli are among the most
important. These bacteria are responsible for maintaining a healthy environment in the
FRT via pH regulation by lactic acid metabolism. Antibiotics eliminate all bacteria from
an environment, including lactobacilli, and as a result, antibiotics are efficacious in the
short run, but due to the lack of lactobacilli, recurrence of BV is possible. While
recurrence is not guaranteed to occur as a result of the lack of lactobacilli, it certainly is
common enough to warrant studies on recurrence prevention, as up to 50% of women
with BV experience recurrence within 1 year of treatment [9]. The proposed solution is a
tandem approach to BV treatment, involving an initial antibiotic treatment followed by
probiotic lactobacillus crispatus (L.cr.) treatment; however, therein lie additional
problems. Probioics are still the topic of investigation for a variety of health issues, and
as such have yet to be clinically proven for BV treatment. As such, in order to investigate
probiotics in the context of BV more efficiently, a mathematical model was built to
simulate L.cr. release and antibiotic release from 3D-printed scaffolds, as well as
associated phenomena such as lactic acid production and pH change. The findings from
this model conclude that the scaffold degradation rate bears the most impact on the time
of release of antibiotic and probiotic from the scaffold, 1-2 days are required in between
antibiotic and probiotic release to avoid any interaction between the two agents, and that
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the release rate from the scaffold provides significant alterations in release kinetics
provided that there is no overlap between antibiotic and probiotic release.
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1. Introduction

According to the Centers for Disease Control and Prevention, 29.2% of women in
the United States between the age of 14 – 49 have bacterial vaginosis (BV) [1]. BV is a
condition which occurs as a result of increased biodiversity in the female reproductive
tract (FRT) due to an imbalance in the microbiota of the female reproductive tract. This
results in an excess of anaerobes, the most prevalent of which is Gardnerella vaginalis
(G.v.). Symptoms include itching, burning during urination, abnormal vaginal discharge,
and foul-smelling vaginal odor [2]. The current standard of treatment for women with BV
is prescribed oral or topical antibiotics to target G.v. and while antibiotics are effective in
getting rid of G.v., the antibiotics also deplete beneficial bacteria , namely lactobacillus
Crispatus (L.cr.). One of the roles of beneficial bacteria is to regulate pH by metabolizing
glucose into lactic acid. BV occurs when these bacteria are overrun by G.v. and the pH
balance is disrupted. Thus, when antibiotics are delivered, they target all bacteria, which
results in efficacy against BV in the short run, but depletion of beneficial bacteria such as
L.cr., often leading to recurrence [9]. Recurrence occurs since, due to the antibiotics
targeting both beneficial and pathogenic species, there are not sufficient beneficial
bacteria present to restore the pH balance. While antibiotic treatment of BV does not
always result in BV recurrence, it also does not provide any countermeasures to prevent
recurrence from happening; the treatment approach for recurrent BV is reactive rather
than proactive. Beneficial bacteria such as L.cr. can be employed as probiotic treatment
for BV to achieve proactive prevention of BV recurrence. This is because when L.cr.
creates lactic acid, the surrounding environment becomes more acidic and, as a result, is

1

more favorable for proliferation of beneficial strains like L.cr. In turn, this helps restore
the balance of bacteria between L.cr. and G.v. since probiotics prefers lower pH
environments (< 4.5) while G.v. prefers higher pH environments (> 4.5) [17] [16][20].
Therefore, the ideal treatment for BV would target G.v. and other pathogenic bacteria
while simultaneously creating a favorable pH environment for L.cr. to proliferate. While
probiotics can certainly be employed to prevent BV recurrence, there are limitations; for
instance, in order to ensure treatment efficacy, probiotics would require frequent, if not
daily applications by the user, which can cause challenges with regard to user adherence
to the treatment. Instead, a mechanism for probiotic delivery that would only require
users to apply the treatment a single time would be ideal.

A solution that has been proposed to meet this need is an electrospun fiber mesh
probiotic delivery system for the sustained release of L.cr. to treat BV. These fibers
consist of hydrophilic polyethylene oxide (PEO) to encapsulate the L.cr., which then
would be electrospun with hydrophobic poly (lactic-co-glycolic acid) (PLGA). While
fibers offer a host of benefits such as biodegradability for sustained release [22], the
spinning procedure itself can be difficult to scale. 3D-printed scaffolds using probiotic
bio-ink are an alternative solution to meet the same need that the PEO-PLGA fiber mesh
does in a more modifiable package. Functionally, the scaffold and fiber mesh are similar
since each allows release of L.cr. into the female reproductive tract (FRT) via
degradation of the delivery vehicle [22]. Additionally, both the fiber mesh and scaffold
release lactic acid to create an initial favorable, acidic environment for the L.cr., albeit
from different sources. In fibers, the initial lactic acid release is caused by the PLGA
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composition of the fiber itself; whereas in scaffolds, bacteria that has been printed into a
scaffold will begin to proliferate and metabolize surrounding nutrients to create lactic
acid, which releases as the scaffold degrades. As these bacteria proliferate, the probiotics
will exhibit chemotactic movement towards glucose in order to survive and proliferate.
As the L.cr. consumes glucose, it creates lactic acid as a metabolic byproduct [12], thereby
creating a more acidic environment and creating a more favorable environment for
further L.cr. proliferation and inhibition of proliferation of G.v. By restoring acidic
conditions, recurrence of BV should be prevented since G.v. viability is hindered in
acidic environments and L.cr. proliferation is favored.

The advantages of probiotic treatment over antibiotic treatment are clear, which begs
the question as to why it has not yet been implemented. Probiotics are still the topic of
many research projects to determine efficacy in initial treatment of BV and effectiveness
in prevention of recurrence. Not to mention, efficacy in initial treatment of BV and
prevention of BV recurrence could be different depending on the delivery vehicle: 3Dprinted scaffold, electrospun fiber mesh, or other delivery means. In soluble co-cultures,
L.cr. has been shown to provide protection against G.v. infection and has also been
shown to outcompete and treat G.v. infection; all of which would indicate that probiotic
treatment of BV in some fashion is by no means a stretch of the imagination. The
viability of probiotic treatment for BV has further been confirmed by success of probiotic
treatment for BV recurrence in clinical trials, such as that of lactin-v and others [33][34].
What remains to be answered though is how best to deliver these probiotics. This is a
fairly significant task, since, not only are there multiple viable delivery means, but there
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is also a myriad of factors associated with each delivery vehicle that alter probiotic
effectiveness: electrospinning parameters, polymer materials, fiber architecture,
morphology, amount of and distribution of the incorporated active agent (the probiotic in
this case), affinity for water, porosity, viscosity, salt and protein concentrations, pH,
system geometry etc. While 3D-printed scaffolds have seen use in soft tissue and
cartilage engineering, delivery of anesthesia agents, and antiviral drug delivery via
intravaginal rings (IVRs) for vaginal applications, specifically the use of such scaffolds
for BV treatment has yet to be explored extensively. These 3D prints have shown
promise in cartilage engineering and soft tissue engineering since the features of a print,
such as geometry, print composition, viscosity, etc., can be precisely modified to fit a
specific need, as was the case for the soft tissue engineering application in Chawla et al.
[25]

, cartilage engineering application in You et al [26], or in IVR synthesis of Janusziewicz

et al. [35]; and can be modified even further via a scaffold’s cross-linking conditions [25].

Since 3D-printed scaffolds for BV treatment is fairly new territory, it is not
immediately apparent how to set scaffold design parameters or how to optimally test
scaffolds, especially considering that laboratory resources such as time or funding are
finite. Previously, mathematical models such as those described in Halwes et al. and
Clark et al. [27] have been immensely helpful in identifying key parameters or predicting
results of interest. Mathematical modeling serves as a useful tool in guiding research
since it allows for the testing of multiple factors independently or codependently in an
accurate and efficient fashion. More specifically, kinetic models enable simulation of
microbial process and predictions for in vitro or in vivo implications. So, in order to
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investigate the 3-D printed probiotic-loaded scaffold as a treatment option for BV, the
existing model from Halwes et al [13] concerning modeling of the fiber mesh probiotic
delivery system will be expanded upon, since the existing model provides a
comprehensive foundation for the modeling of probiotic release from 3-D printed
scaffolds. The nature of probiotic release is quite different from drug release, however,
since the movement of the drug is modeled via simple diffusion while the movement of
the probiotic is dependent on a variety of factors. The existing computational MATLAB
model was adapted to fit release specifications of 3D-printed scaffolds, simulate probiotic
release patterns, simulate pH change, and test a variety of factors related to probiotic
efficacy and recurrence prevention. Such a model will be able to steer research on
probiotic treatment for BV desirable features for a probiotic 3D-printed scaffold.

2. Instrumentation and Equipment
The majority of modeling work was done within MATLAB R2020b, although the
model can be run on any version of MATLAB since 2013, as MATLAB R2013a has also
been used to run the model. Moreover, a device with minimum 16 gigabytes RAM is
required to run the model; however, that amount of memory is only sufficient to sustain
240 hours of model runtime. If more simulation time is required, a device with more
RAM would be required. The RAM limitation does not affect the model’s ability to
produce an accurate solution, however. If attempting to run the model past a device’s
RAM limitation (i.e., trying to simulate 500 hours on a device with 16 GB RAM, which
would only allow 240 hours simulation), the model runs such that the maximum amount

5

of data is stored before running out of memory, and then the program is stopped. This
means that the solution obtained from such a run will still be accurate but will not contain
values past the RAM limitation. In other words, if one tries to simulate 500 hours on a
device that only allows 240 hours of simulation, MATLAB will function as expected and
accurately simulate the 240 hours, however once the program is out of memory,
MATLAB will stop running the code and there will not be a solution present for the
remaining 360 hours.

3. Procedure

3.1 Original Model
The existing model describes the release profile of an antiviral drug from a PEOPLGA nanofiber mesh delivery vehicle, which serves as the foundation for modeling 3Dprinted probiotic scaffolds. The original model sets the geometry, restraints, domain, and
degradation kinetics that are used in the additions to the model.

3.1.1 System Geometry
The geometry set by the original model represents a sample of fiber mesh placed
over a layer of vaginal tissue, which is intended to mimic the in vivo environment of the
FRT. The fiber mesh is in fluid, whose domain is computationally represented as a
cylinder with radius 0.5 cm (rF) and thickness 0.5 cm (hF). The fibers, which are modeled
as cylinders, are treated as uniform, neglecting any variance between fibers.
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Figure 1: System geometry: (A) Isometric view of the system geometry, (B) system cross-section. The figure itself is
from Halwes et al. [13], since the geometry from the aforementioned study remained unchanged.

3.1.2 Fiber Degradation
Since PLGA can form polymer chains upwards of 10,000 repeating units,
statistical moments were applied to polymer chains of length n > 9,
∞

𝜇𝑘 = ∑((𝑛)𝑘 𝐶𝑛 )
𝑛=1

(1)

where the kth statistical moment depends on the degree of polymerization n and
concentration of polymers of n chain length Cn. Thus, μ0 is the concentration of polymer
per unit volume, μ1 is the concentration of monomers per unit volume, and μ2 represents
polymer polydispersity. From these three statistical moments, the polymer concentration
change in time can be defined.
𝜕𝐶𝑀
1 𝜕
𝜕𝐶𝑀
=
(𝐷𝑀 𝑟
) + 2𝑘𝑑 𝐶𝑊 (𝜇0 − 𝐶𝑀 )𝜇0
𝜕𝑡
𝑟 𝜕𝑟
𝜕𝑟
( 2a )
𝑛

𝜕𝐶𝑛
1 𝜕
𝜕𝐶𝑛
=
(𝐷𝑛 𝑟
) + 2𝑘𝑑 𝐶𝑊 (𝜇0 − ∑ 𝐶𝑗 ) 𝜇0 − (𝑛 − 1)𝑘𝑑 𝐶𝑊 𝐶𝑛 𝜇0
𝜕𝑡
𝑟 𝜕𝑟
𝜕𝑟
𝑗=1
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2≤𝑛≤9
( 2b)

CM and CW represent the concentration of polymer monomers and concentration of water,
respectively, while r represents the cylinder radius, DM and Dn represent the diffusion
coefficients of monomer and polymer oligomer in water, and kd is a kinetic rate constant
for fiber degradation. Additionally, the diffusion of water into the polymer matrix can be
modeled as follows:
𝜕𝐶𝑊
1 𝜕
𝜕𝐶𝑊
=
(𝐷𝑊 𝑟
) − 𝑘𝑑 𝐶𝑊 (𝜇1 − 𝜇0 )𝜇0
𝜕𝑡
𝑟 𝜕𝑟
𝜕𝑟
(3)

since PLGA is classified as a bulk erosion polymer.

Using the statistical moments, diffusion and degradation of polymers of chain
length greater than 9 can be defined.
9

𝜕𝐶𝑗
𝜕𝜇0
1 𝜕
= ∑
(𝐷𝑗 𝑟
) + 𝑘𝑑 𝐶𝑊 (𝜇1 − 𝜇0 )𝜇0
𝜕𝑡
𝑟 𝜕𝑟
𝜕𝑟
𝑗=1

( 4a )
9

𝜕𝐶𝑗
𝜕𝜇1
𝑗 𝜕
= ∑
(𝐷𝑗 𝑟
)
𝜕𝑡
𝑟 𝜕𝑟
𝜕𝑟
𝑗=1

( 4b )
9

𝜕𝐶𝑗
𝜕𝜇2
𝑗2 𝜕
𝑘𝑑 𝐶𝑊 𝜇0
𝜇22 𝜇2 𝜇1
= ∑
+
(𝐷 𝑟
)+
(𝜇1 − 2
)
𝜕𝑡
𝑟 𝜕𝑟 𝑗 𝜕𝑟
3
𝜇1
𝜇0
𝑗=1

( 4c )
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Equations (2), (3), and (4) define polymer degradation and diffusion in the model and are
relied on for drug and probiotic release.

3.1.3 Drug Release
In addition to utilizing fiber degradation from Halwes et al.[13], the drug release
from this model is adapted for an antibiotic.
𝜕𝐶𝐷
1 𝜕
𝜕𝐶𝐷
=
(𝐷𝐷,𝑒𝑓𝑓 𝑟
)
𝜕𝑡
𝑟 𝜕𝑟
𝜕𝑟
(5)

The drug concentration CD change in time depends on itself, the cylinder radius, and the
effective diffusion coefficient of drug through the polymer matrix DD,eff. This diffusion
changes in time since as the fibers degrade, there is a decrease in hindrance to diffusion
by the polymer chains, resulting in increased diffusivity.
0.5

𝐷𝑖,𝑒𝑓𝑓 =

0
𝐷𝑖,𝑒𝑓𝑓
exp [2.5 (1

𝑀𝑊𝑛 (𝑡, 𝑟)
−
)
𝑀𝑊𝑛 (𝑡 = 0)

]

(6)

Di,eff denotes the effective diffusion coefficient of a particular species: monomer,
oligomer, water, or drug, while Di,eff0 is the initial condition for each respective diffusion
coefficient. Here, MWn is calculated as
𝑀𝑊𝑛 =

𝜇1
𝑀𝑊𝑚𝑜𝑛
𝜇0
(7)

and is the number-averaged molecular weight, with MWmon representing the molecular
weight of the monomer.
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3.1.4 Boundary Conditions
The final element from Halwes et al. to be incorporated is the definition of boundary
conditions of which there are two boundaries considered: the center of the fiber (r = 0)
and its edge (r = R). Since symmetry is assumed at the fiber center, this yields the
following:
𝜕𝐶𝑖
|
=0
𝜕𝑟 𝑟=0
( 8a )

𝜕𝐷𝑖
|
=0
𝜕𝑟 𝑟=0
( 8b )

with Ci as the concentration of a species and Di as its diffusion coefficient.
Since mass transfer occurs at the fiber edge and involves drug molecules, monomers,
oligomers, water, and probiotics to the surrounding aqueous environment, the boundary
condition is as follows:
−𝐷𝑖 (𝑟 = 𝑅)

𝜕𝐶𝑖
𝑒𝑥𝑡
|
= 𝑘𝐶,𝑖
(𝐶𝑏,𝑖 − 𝐶𝑖 (𝑟 = 𝑅))
𝜕𝑟 𝑟=𝑅
(9)

Here, Cb,i is the concentration of a particular species in the exterior environment, which is
assumed as 0 for the monomer, oligomer, and drug and 0.055 mol cm-3 for water . The
assumption of 0 is based on the turnover of surrounding fluid in physiological systems,
which resembles a sink condition. The Sherwood number is used to estimate the mass
transfer coefficient kC,iext. The Sherwood number is a dimensionless number utilized in
mass transfer to find the ratio of convective mass transfer to diffusive mass transport. For
fluid flow over a cylinder, the Sherwood number
10

𝑒𝑥𝑡
2𝑘𝐶,𝑖
𝑅
𝑆ℎ = 2 =
𝐷𝑖,𝑤

( 10 )

depends on the radius of the cylinder R and the diffusion coefficient of each species Di,w.

3.2 Probiotic and Scaffold Adaptations
With the foundations for fiber degradation, drug release, and boundary conditions
set, the model by Halwes et al. can be adapted to accommodate probiotic release and
scaffold degradation, as well as other related, crucial components such as glucose
concentration, lactic acid concentration, lactic acid dissociation, and pH.

3.2.1 Scaffold Degradation
The model domain from Halwes et al [13] is a sample of an electrospun polylactic-coglycolic acid (PLGA) fiber mesh in fluid, which is placed over a layer of vaginal tissue.
In the original model, the interior of a single fiber served as the model domain; whereas
now, the model domain is the interior of a single scaffold. More specifically, the model
describes the interior of a single 3D-printed scaffold as the delivery vehicle, with a
porous exterior containing antibiotic, and a gelatin-alginate interior containing L.cr.
Geometrically, the two delivery vehicles are similar, so from a modeling perspective,
there are two functional differences to address. The first of these is the compartmental
nature of the scaffold versus the fiber mesh. Scaffolds can be printed using a combination
of inks, each with their own composition. Therefore, the interior of the scaffold can be
printed with probiotics while the exterior is printed with the antibiotic. As the scaffold
degrades from the exterior inwards, there is an initial release of antibiotic, followed by
11

release of probiotic. The compartmental nature of the scaffold is modeled by
implementing a delay in the form of a unit step function on the release of the probiotic.
The delay is based on the status of scaffold degradation; if and only if the scaffold has
degraded to a user-defined amount, probiotic release occurs, shown below.
∑9𝑖=1 𝐶𝑖
≥ 𝑇, 𝑇 ∈ [0,1]
𝑆 = {1, 𝜇0
0,
otherwise
( 11 )

S represents the condition that determines whether or not there will be probiotic release,
Ci represents the concentration of polymer chains of length 1 (monomer) to 9, μ0
represents the total polymer concentration, and T represents the threshold at which
release occurs, which is a value between 0 and 1. Ci is constantly updated in time so if the
ratio of polymer constituents to total fiber concentration is greater than or equal to the
user-defined threshold, 1 is set for the value of S and probiotic release occurs. Otherwise,
the value for S is 0, and probiotic release does not occur.

The second functional difference between the fiber mesh and scaffold to address is
the rate at which release occurs from each vehicle. Release is governed mainly by fiber
geometry and fiber degradation rate. Worth noting is that the mechanism of degradation
is not of interest in this model and so while there may be differences between the
mechanisms of fiber degradation and scaffold degradation, we are only interested in the
functional difference between the two. In other words, while the mechanism of scaffold
degradation may be different from fiber degradation, the modeled fiber degradation can
be adapted to reflect scaffold degradation. Worth mentioning is that pore sizes between
the fiber and the various compartments of a scaffold are different depending on the
12

composition of each vehicle. However, since the same geometry is assumed between the
scaffold and fiber, this extends to the pore sizes as well. Moreover, since the fiber mesh
geometry is applied to the scaffold, the degradation rate of the fiber mesh is all that
remains be adjusted in order to accurately model a scaffold. Scaffolds tend to degrade
more slowly than fibers [27], so the degradation rate was calibrated to reflect this. The
desired output for probiotic release was such that probiotic release would not coincide
with a substantial concentration of antibiotic, so the degradation rate was calibrated
accordingly. The degradation rate was calibrated to acquire delays of varying lengths; a
narrow range of the degradation rate that would provide close to the desired delay was
established via estimation, then linear regression was used to find the degradation rate
value that corresponded to the desired delay.

3.2.2 Probiotic Release
The first addition to the existing system is the modeling of probiotics, which requires
consideration of modeling live organisms as opposed to chemical compounds.
Realistically, the probiotics do not release from the scaffold the same way a drug would;
where a drug’s behavior can be considered homogenous between spatial points, each
probiotic is an individual organism that behaves slightly incongruously from another
probiotic at a different spatial point, in addition to the fact that probiotics are much larger
than an individual drug molecule, and probiotics also begin proliferating after release. In
order to accurately model probiotic behavior, the live nature of the probiotic must be
considered. The number of probiotics within a scaffold can be up to 5 × 107 colony
forming units (CFUs) [22], so treating each of these as an individual organisms would be
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computationally strenuous. As such, the approach to modeling the probiotic requires the
assumption that each individual probiotic can be treated as an aggregate organism and
that any idiosyncratic behavior from the probiotics can be considered negligible overall.

With this assumption made, the nature of probiotic release must be considered.
Unlike a drug, the movement of probiotics is not solely dependent on simple diffusion;
there are chemotactic elements to examine with probiotics that are not present with a
drug. Firstly, probiotics will exhibit chemotaxis towards glucose since this is the source
of their nutrient which is required for proliferation as well as lactic acid production [15].
Since glucose allows for probiotic survival, chemotaxis towards glucose is a stronger
influence on probiotic movement than simple diffusion [15]. As mentioned previously,
probiotic consumption of glucose allows probiotics to produce lactic acid, which is
another important factor for probiotic survival as well as the second chemotactic element
of probiotic movement. The probiotics produce lactic acid thereby lowering the pH of the
surrounding environment and helps create a more favorable environment for probiotic
survival [12]. Therefore, chemotaxis towards lactic acid can be considered a stronger
influence on probiotic movement than simple diffusion, but not as strong as chemotaxis
towards glucose. The equations governing probiotic release incorporate glucose
concentration, lactic acid concentration, antibiotic concentration, as well as scaffold
degradation.
𝑑𝐶𝑝
= (𝑘𝑃 ∙ 𝐶𝑃 − 𝑘𝑑 ∙ 𝐶𝑃 − (𝑘𝐴𝐷 ∙ 𝐶𝐷 + 𝑘𝑅 ∙ (𝜇0 − 𝜇0,𝑡 )) ∙ 𝐶𝑃 ) ∙ 𝑆
𝑑𝑡
( 12 )

𝑘𝑃 = 𝑘𝑃𝑚𝑎𝑥 ∙ (

𝐶𝐺
𝐶𝐴
) ∙ (1 −
)
𝐾𝑆 + 𝐶𝐺
𝐶𝐴𝑚𝑎𝑥

14

( 13 )

The change in probiotic concentration (Cp) over time is expressed in equation (12) while
the growth rate of probiotics kp is expressed in equation (13). First and foremost, all terms
in the probiotic equation are multiplied by the unit step function S, which indicates that
until there has been sufficient degradation of the polymer, there is no significant change
in the probiotic behavior. When the unit step function is evaluated as 1, the probiotic
concentration is dependent on itself, the probiotic death rate kd, the death rate due to
antibiotic interaction kAD, the release rate of probiotic from the scaffolding kR, the total
polymer concentration μ0 and μ0,t, and the unit step function S, as defined in equation
(11). Probiotic growth cannot be treated as constant, since the growth is usually a
function of the system’s environment and time. Instead, probiotic growth kp follows the
Michaelis-Menten model of enzyme kinetics applied by Monod to microorganism growth
[21]

. The Monod model accounts only for the nutritional limitation of probiotic growth by

glucose affinity; however, the contribution and inhibition of probiotic growth by
probiotic lactic acid production must also be considered. The probiotic growth rate is
always a fraction of kPmax, which is the maximum growth rate of the probiotic. The
magnitude of this fraction is dependent on the glucose concentration CG, the probiotic
affinity for glucose or half-velocity constant KS, the lactic acid concentration CA, and the
maximum lactic acid concentration CAmax. Probiotic concentration, and by extension
probiotic growth rate, will increase or decrease depending on how much glucose is
available; high glucose will result in more proliferation while low glucose results in the
opposite, which is accounted for by the Monod model. Probiotic proliferation rate also
depends on lactic acid concentration since a primary function of probiotics in the FRT is
to regulate pH, which is achieved by lactic acid production by probiotics. However,
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probiotics will not proliferate as readily if there is already sufficient lactic acid in the
environment, as the undissociated form of lactic acid is a main inhibitor of probiotic
growth [5][11]. Undissociated lactic acid also serves as an indicator of the favorability of an
environment for probiotics; once the concentration of lactic acid reaches its optimal point
in the environment to host probiotics, the probiotics will maintain that concentration by
either increasing or decreasing probiotic growth as needed. This relationship with lactic
acid concentration can be expressed utilizing Briggs-Haldane kinetics (a derivation of the
Michaelis-Menten model) [28][29] and is represented by the second parenthetical term in
the probiotic growth rate equation.

Aside from kP, the rest of the terms in the probiotic equation contribute to loss of
the probiotic from different sources. The first loss term is kd, which represents general
death of probiotic and is assumed constant. This assumption is possible since fluctuations
in death rate due to glucose or lactic acid concentration are already considered in the
probiotic growth rate. While the death rate kd does not change, kP does change as the
environment becomes more or less favorable for the probiotic which results in a relative
change between the growth rate kP and the death rate kd. Bear in mind that the model
domain only consists of a single scaffold, and while kd accounts for some probiotic loss
from the scaffold, there are two additional sources of probiotic loss: probiotic-antibiotic
interaction and the release of probiotic from the scaffold, which are represented by kAD
and kR, respectively. Since antibiotics used to treat BV do not selectively target bacteria,
if there is any overlap between probiotic and antibiotic release, the antibiotics will
immediately kill the probiotic. Additionally, kR represents the rate at which bacteria are
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released from the scaffold and move towards glucose as the scaffold degrades. The
release rate kR is multiplied by the term μ0 - μ0,t which decreases the release rate as the
scaffold degrades. More specifically, μ0,t is the polymer concentration at the first point
where the ratio of oligomers of chain length 1 – 9 to the total polymer concentration is
greater than or equal to the user-defined threshold; or, more simply put, it is the polymer
concentration at the first point at which the unit step function S is equal to 1. In order to
determine the value for μ0,t, the model must be ran to the point at which S is equal to 1;
however, while this is feasible, it is not ideal to retroactively implement values for
parameters. Therefore, until the value for μ0,t is known, it is initialized to 0. Then once the
condition for S has been met, the value for μ0,t is updated. The effect that this has on the
release rate kR is that once the condition has been met, μ0 increases as the scaffold
degrades while μ0,t remains constant. This causes an increase in the release rate kR due to
the fact that as more of the scaffold has degraded away, the more readily and easily the
probiotics can exit the scaffold.

3.2.3 Glucose and Lactic Acid Modeling
Glucose and lactic acid are crucial components of probiotic proliferation and
survival, so the model would not be complete without their consideration. Note that
diffusion has not been considered for glucose or lactic acid since the scaffold has a
porous surface. This allows for an equilibrium to be assumed between the scaffold and
the surrounding environment.
𝑑𝐶𝐺
= 𝐺𝐺 − 𝐿𝐺 𝐶𝐺 − 𝑘𝐺 𝐶𝑃 + 𝑓𝐺
𝑑𝑡
( 14 )
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𝑑𝐶𝐴
= (𝐺𝐴 − 𝐿𝐴 𝐶𝐴 + 𝑘𝐴 𝐶𝑃 + 𝑓𝐴 ) + (𝑘𝑟 ∙ ℓ ∙ 𝑎 − 𝑘𝑓 ∙ 𝐶𝐴 )
𝑑𝑡
( 15 )

The glucose equation and the first parenthetical term in the lactic acid equation follow the
same format. Each equation has a gain term G, loss rate due to leakage L, forcing
function f, and probiotic-related rate k. The gain term G represents entrance of the
substrate into the system from the environment, while the subscripts G and A denote
glucose and lactic acid, respectively. The rates kG and kA
𝑘𝐴 , 𝑘𝐺 ∝ 𝑘𝑃
( 16 )

𝑘𝐺 =

𝑘𝑃
𝑌𝑃/𝐺
( 16a )

𝑘𝐴 =

𝑘𝐺
𝑌𝐴/𝐺
( 16b )

represent probiotic consumption of glucose and probiotic production of lactic acid and
are proportional to the probiotic growth rate. The glucose consumption and lactic acid
production rates are not constant during glucose fermentation since these rates are
affected by rate of probiotic growth and substrate consumption [19]. The glucose
consumption rate is dependent on probiotic growth kP and a constant YP/G probiotic
growth yield from glucose. The probiotic production rate of lactic acid is dependent on kG
and a constant YA/G which represents the lactic acid yield from glucose metabolism.
Additionally, fG and fA are forcing functions for glucose and lactic acid which help restore
or maintain steady-state conditions of each substrate. The lactic acid forcing function fA
represents lactic acid released from the PLGA-PEO fiber mesh, however this is negligible
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when compared to the lactic acid production by probiotics. Moreover, the glucose forcing
function fG is also set to 0 since the other terms already maintain an equilibrium. The
forcing functions were essentially infrastructure from the original model that were not
needed for the new equations.

3.2.4 Lactic Acid Dissociation
The lactic acid equation also contains reaction kinetics from its dissociation that
contribute to the overall lactic acid concentration. The dissociation’s contribution to
overall lactic acid concentration is represented by the second set of terms in equation (5).
Moreover, the dissociation of lactic acid is necessary in order to measure pH and gauge
the effect of probiotics. Lactic acid, C3H6O3, dissociates into a lactate ion and hydrogen
ion with forward and reverse rates kf and kr.
𝑘𝑓

𝐶3 𝐻6 𝑂3 ⇌ 𝐶3 𝐻5 𝑂3− + 𝐻 +
𝑘𝑟

( 15a )

𝐾𝐴 =

𝑘𝑓
𝑘𝑟
( 15b )

𝑘𝑟 =

𝑘𝑓
𝐾𝐴
( 15c )

The forward and reverse rates were determined from the equilibrium constant of lactic
acid dissociation KA, which is equal to 1.38 ×10-4. From here, kf was estimated and the
corresponding kr was calculated. From the lactic acid dissociation, equations governing
the dissociation equilibrium can be formulated,
𝑑𝐶𝐴
= 𝑘𝑟 ∙ ℓ ∙ 𝑎 − 𝑘𝑓 ∙ 𝐶𝐴
𝑑𝑡
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( 15d )

𝑑𝑎
= 𝑘𝑓 ∙ 𝐶𝐴 − 𝑘𝑟 ∙ ℓ ∙ 𝑎
𝑑𝑡
( 15e )

𝑑ℓ
= 𝑘𝑓 ∙ 𝐶𝐴 − 𝑘𝑟 ∙ ℓ ∙ 𝑎
𝑑𝑡
( 15f )

where CA represents the lactic acid concentration, ℓ represents the lactate ion
concentration, and a represents the acidic hydrogen ion concentration, all expressed in
mol/mm3. The equations for lactate ion and H+ follow the same kinetics, however they
differ in their initial conditions which results in similar trends in their behavior but
ultimately different equilibrium values.

3.2.5 pH Calculation
Since the H+ ion concentration, a, is initially expressed in mol/mm3, a unit
conversion is required to accurately calculate pH, since the pH equation requires a
concentration expressed in molarity.
𝑝𝐻 = −𝑙𝑜𝑔10 (𝑎 ∙ 106 )
( 17 )

Here, 106 serves as the conversion factor from mol/mm3 to mol/L, and hence molarity.

Table 1: System Parameters
Parameter Definition
kd
General probiotic death rate

Value (Range)
2.473 × 10-3 h-1
(2.47 × 10-3 to 2.476 × 10-3 h1
)

Source
Calibrated

kD

6.79 × 10-2 h-1
(0.44 to 1.9 h-1 )

Calibrated

Degradation rate constant
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kPmax

Maximum probiotic growth
rate

1 h-1
(0.95 to 1.03 h-1 )

kAD

Probiotic death rate due to
antibiotic interaction
Release rate of probiotic from
scaffold
Half-velocity constant for
probiotics and glucose

1.25 × 102 h-1
(1.0 × 102 to 1.0 × 103 h-1)
5 × 10-1 h-1
(5 × 10-2 to 1 h-1)
2 × 10-1 mol/mm3
(1.95 × 10-1 to 2.05 × 10-1
mol/mm3)

CAmax

Maximum lactic acid
concentration

GG

Glucose gain

GA

Lactic Acid gain

LG

Loss rate of glucose due to
leakage
Loss rate of lactic acid due to
leakage
Yield of probiotic growth
from glucose consumption
Yield of lactic acid from
glucose consumption
Lactic acid dissociation
equilibrium constant
Forward rate of lactic acid
dissociation

6.03 × 10-5 mol/mm3
(5.0 × 10-5 to 7.12 × 10-5
mol/mm3))
1 × 10-4 mol/(mm3∙h)
(1.0 × 10-5 to 1.1 × 10-4
mol/(mm3∙h)
6 × 10-7 mol/(mm3∙h)
(5 × 10-7 to 7 × 10-7
mol/(mm3∙h))
1 × 10-1 h-1
(6.0 × 10-2 to 1.023 × 10-1 h-1)
2 × 10-2 h-1
(1.1 × 10-2 to 2.08 × 10-2 h-1)
1 × 101
(2.0 to 5.0 × 101)
1.8

kR
KS

LA
YP/G
YA/G
KA
kf

Literature
[24]
,
calibrated
Calibrated
Calibrated
Literature
[24]
,
calibrated
Literature
[30]
,
calibrated
Calibrated

Calibrated

Calibrated
Calibrated
Calibrated
Literature
[31]

-4

1.38 × 10

Literature
[23]

-9

1.38 × 10 mol/L
(1.38 × 10-11 to 1.38 × 10-7
mol/L)

Calibrated

All rates are multiplied by the units of concentration in the model, mol/mm3, which
ultimately yields units of concentration per time, mol/(mm3∙h).

Table 2: System Variables
Variable
Ci

Definition
Polymer oligomer concentration for i = 1, 2…,9

μ0

Concentration of polymer per unit volume
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μ0,t

Concentration of polymer per unit volume at first timepoint where S = 1

kP
CG
CA
kG
kA
kr
ℓ
a
kD
T

Probiotic growth rate
Concentration of glucose
Concentration of lactic acid
Probiotic consumption rate of glucose
Probiotic production rate of lactic acid
Reverse rate of lactic acid dissociation
Lactate ion concentration
H+ ion concentration
Degradation rate constant of fiber
Scaffold degradation threshold that must be met before probiotics release

3.2.6 Parameter Calibration
Several system parameters were calibrated to their current value, as opposed to
being obtained via literature or calculation. This calibration process was based on system
stability, system efficiency, biological relevance, and literature. Whenever possible,
literature values were used to obtain an initial value for a parameter, around which a
range of values could be found. The range for literature values was established by mainly
considering system stability and efficiency. For system stability and efficiency, the
calibration of parameters was fairly consistent; if a value for a given parameter causes the
system to be unable to converge to a solution or if said value causes erratic or nonsensical
system behavior, that parameter value would not be included in the range. An example of
erratic system behavior would be if a given parameter value results in an irregular
waveform, whereas an example of nonsensical system behavior would be negative values
for a system variable for which negative values are realistically impossible within the
system, such as probiotic concentration, glucose concentration, lactic acid concentration,
etc. System stability and efficiency were considered for all parameters, however there
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were some parameters for which system stability and efficiency were the only
considerations for calibration since they would typically have small ranges of values for
which the system could converge to a solution and would have little change in system
behavior across the range of values for which a solution was obtained. These parameters
were GG, GA, and YP/G.

While the approach to calibration with respect to system stability and efficiency
was fairly uniform across system parameters, calibration with respect to biological
relevance was more varied depending on the system parameter. For instance, the general
probiotic death rate kd was calibrated such that probiotic growth would not outpace
probiotic death, resulting in the scaffold serving as an endless well of bacteria. If the
death rate was too low, growth would occur uncontested and unfettered; however, if the
death rate was too high, probiotics would simply die in the scaffold as opposed to being
released. The calibration of the maximum probiotic growth rate kPmax followed a similar
approach; if the maximum growth rate was too high, unrestrained growth would occur,
while if it was too low, probiotic death would be dominant at equilibrium.

The scaffold degradation rate kD was calibrated based on the desired delay. This
was adapted from Halwes et al.[13] and varied to determine the relationship between kD
and corresponding delay. Once this relationship was established, the degradation rate was
calibrated to find various lengths of delay.
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The probiotic death rate due to antibiotic interaction kAD was calibrated such that if
there was significant overlap between antibiotic and probiotic release, this death rate
would cause the probiotic concentration to be quickly exterminated by the antibiotic.
Making this rate too low would correspond to the antibiotic causing an insufficient
amount of probiotic death; however, making this rate too high would result in the
probiotic dying off if there is any presence of antibiotic, regardless of concentration. Both
of these phenomena would not be realistic since antibiotics in sufficient concentration
will kill off any bacteria, but if 99% of the antibiotic has already released into the FRT,
the remaining 1% of antibiotic would not be sufficient to eliminate all probiotics from the
scaffold.

The release rate kR was calibrated such that decay due to kR would be
distinguishable from decay due to kAD, the probiotic death rate due to antibiotic
interaction. As such, kR would need to be sufficiently low in order to produce a
pronounced decay curve, while kAD would produce a decay curve that is immediate. A
range of values was obtained based on the need to be able to attribute the cause of decay
to either probiotic interaction with antibiotic or release from the scaffold. At the higher
end of this range, it is more difficult to discern this, while it is easier at the lower end of
the range. This is because a higher release rate yields more rapid probiotic decay, while a
lower release rate yields a more pronounced decay. If the release rate is set sufficiently
high, it is not possible to visually determine whether probiotic decay is occurring due to
interaction with the antibiotic or due to the exit of probiotic from the scaffold. If,
however, the release rate is set sufficiently low, this distinction is easier to make since a
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pronounced decay would be caused by the release rate while a rapid decay would be
caused by antibiotic interaction.

The calibration for the loss rate of glucose and lactic acid due to leakage LG and LA,
respectively, utilized a similar approach, although the end goals for calibration of these
terms were different. For glucose, the expectation is that there is sufficient glucose for the
probiotics such that competition for nutrients does not factor into the probiotic
concentration equilibrium. This is due to the fact that the scaffold itself is porous to the
exterior environment and as the concentration of glucose inside the scaffold decreases, it
is replenished by the entrance of glucose from outside the scaffold. Additionally,
competition for glucose was not considered since only L.cr. was modeled; the presence of
other bacteria was not considered due to the model domain consisting solely of the
interior of a scaffold. With these considerations, the loss rate of glucose due to leakage
could not be too high that it would result in system failure but could not be so low that
the glucose concentration would decrease to 0 inside the scaffold. The loss rate of lactic
acid due to leakage LA was calibrated in a similar fashion; however lactic acid is expected
to be released from the scaffold, unlike glucose. This is because the environment in
which a scaffold is deployed would be the environment of a BV infection where pH is
high and lactic acid concentration is low. As such, lactic acid from inside the scaffold
would be expected to release into the environment after being produced by the probiotics
in the scaffold. This is reflected in the calibration of LA since making this rate too low
would cause lactic acid to be produced unrestricted inside the scaffold, and it would make
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the scaffold an endless well of lactic acid, while making the rate too high would result in
system instability.

3.3 Verification
The model results were verified via analytical confirmation. The model was run and
stopped at a random point where manual calculations for system variables at this point
were made in Excel and compared to model calculations for the same variables. Upon
assessment, the manual calculations were the same as the model calculations, with slight
discrepancies due to floating point approximation in Excel. Since MATLAB and Excel
can only be so precise in terms of storing values for floating point numbers, there were
slight differences between manual and model calculations, but these differences were on
orders of magnitude smaller than the precision of both MATLAB and Excel. In the
model, the variables were stored with up to 15 digits of precision and Excel uses 15 digits
of precision by default [36][37][38]. The maximum difference between manual and model
calculations was 1.08 × 10-18 which is on an order of magnitude beyond the precision of
MATLAB and Excel, which confirms that floating point approximation as the cause for
this difference since there were no recorded differences within the precision of MATLAB
or Excel. This method of analytical confirmation was possible since the model
calculations are not stochastic; hence, if the calculations are correct at one point in the
model, they are correct at any other point in the model since the calculations are rigid in
terms of how they are made.

3.4 Validation
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Currently, the modeling results are theoretical and as such have not yet been
experimentally validated. Nonetheless, steps are in place for model validation; the first of
which is to validate the scaffold degradation timeline. This would be done in 3 parts: (1)
determining the scaffold degradation timeline for a scaffold printed with only L.cr., (2)
determining the scaffold degradation timeline for a scaffold printed with only antibiotic,
and (3) determining the scaffold degradation timeline for a scaffold printed with both
L.cr. and antibiotic. Blank scaffolds (scaffolds without bacteria) would also be printed to
serve as a comparison for how bacteria affect scaffold degradation. These three parts
would establish baseline expectations for how long a scaffold would degrade and how
each agent (L.cr. and antibiotic) affects degradation. To do this, scaffolds would be
printed with bioinks of various compositions, as specified earlier, then placed in
simulated vaginal fluid [32] (SVF) in a 37°C environment, such as an incubator. These
scaffolds would be assessed daily for structural integrity to determine exactly how long it
takes for the scaffold to degrade entirely. Then, the timeline for degradation of the
scaffolds can be implemented more precisely in the model.

The next step for validation would involve validating the probiotic release and
associated effects of the probiotic on the surrounding environment. Validating probiotic
release, at least as it has been presented in the model, is not straightforward. This is due
to the nature of release from scaffolds itself; when a probiotic-loaded scaffold is
delivered into an aqueous environment, the scaffold will eventually release some initial
amount of CFUs of the probiotic, in this case L.cr. When this occurs, the CFUs that have
been released eventually begin proliferating on their own, while the scaffold is
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simultaneously releasing additional CFUs of L.cr. Release from a scaffold can be
measured, however it is not feasible to distinguish the probiotics that have released from
the scaffold itself and the probiotics that have grown as a result of a prior CFU being
released from the scaffold and proliferating. The model domain consists of the interior of
a scaffold, and as a result, proliferation of probiotic on the exterior of the scaffold, be it
from released or surface-bound L.cr., is not considered in any probiotic release curves. In
other words, since the in vitro release of probiotics from a scaffold cannot be separated
from the proliferation that occurs as a result of said release, it is not currently possible to
validate the modeled probiotic release. This is because the model domain only consists of
the interior of a scaffold, and as a result, only release is modeled, not proliferation. With
that said though, other probiotic-related phenomena can still be validated; namely, the pH
change. This can be done simultaneously with validating the scaffold degradation
timeline. For scaffold degradation validation, probiotic-only, antibiotic-only, and
probiotic-antibiotic scaffolds would be printed and placed in SVF and assessed daily for
structural integrity. Additional assessments can be made to determine pH change; the
initial pH of SVF would be measured, then pH would be measured at various timepoints.
The timepoints of interest would likely be 1-hour, 4-hour, then daily for at least 10 days.
These timepoints would help establish the rate by which probiotics cause surrounding pH
to change, which can be incorporated into the model. Note that this would also provide
validation for the Briggs-Haldane basis of probiotic growth modeling, which treats lactic
acid as an inhibitor of probiotic growth. Since lactic acid is the primary determinant of
pH [5][11] in the FRT, pH can be treated as a proxy for lactic acid, as undissociated lactic
acid increases pH, and the dissociation of lactic acid causes decreased pH. If the pH
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decreases to a particular point and then remains at that level, it would suggest that pH and
lactic acid provide some inhibitory effect on probiotic growth, thereby validating the
modeling approach to probiotic growth.

4. Results and Discussion of Results

4.1 Release of Probiotic

In order for probiotics to affect their surrounding environment, they must be
released such that they do not interact with the antibiotic; otherwise, they will be killed
by the antibiotic and will exert negligible effect on the restoration of vaginal health. The
most efficient way to delay this release is by altering the scaffold degradation rate kd,
since release occurs as a function of scaffold degradation. Hence, the relationship
between the degradation rate and time of release was determined.
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Figure 2: Time of Release vs. kD. As fiber degradation rate increases, the corresponding delay of time of probiotic
release is shortened. The points from left to right correspond to (0.05, 72), (0.07, 48), (0.13, 24), (0.23, 12), and (0.44,
6).

The relationship between kD and corresponding time of release appears to follow a
negative logarithmic curve where, as kD is increased further and further, the time of
release is delayed further, albeit to a lesser and lesser extent. To utilize this insight, a
variety of probiotic release profiles were obtained, all of which had varying degradation
rates which equated to different lengths of delays: 6-hour, 12-hour, 1-day, 2-day, and 3day. The drug release from the model reaches 100% drug released in approximately 1.5
days, which means a delay of probiotic release by two days would avoid any interaction
with the antibiotic.
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Figure 3a-b: (a) Probiotic Release Profile with varying time-delays as a result of varying scaffold degradation rate: 6hour delay, 12-hour delay, 1-day delay, 2-day delay, and 3-day delay. (b) Time to reach various probiotic release
checkpoints (25%, 50%, 75%, and 95%) vs. corresponding delay in hours (72, 48, 24, 12, 6). The green diamonds
represent 25% probiotic release, the blue circles represent 50% probiotic release, the red squares represent 75%
probiotic release, and the yellow triangles represent 95% probiotic release. The R2 correlation coefficient for each set of
data was above 0.9.

Based on the release profiles from the model, delays of less than 1 day on the probiotic
release are susceptible to antibiotic interaction, so a delay of at least 1 day would be
required between antibiotic and probiotic release to ensure probiotic efficacy. This also
indicates that the drug concentration at the 1-day mark is not sufficient to cause
significant loss of the probiotic due to antibiotic interaction. These delays were achieved
by adjusting the degradation rate kD; thus, an increase in degradation rate translates to
faster release and a shorter delay of probiotic release.

The probiotic release can also be assessed by the time at which it reaches various
probiotic release checkpoints (10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%,and
95% release) compared to the associated delay. This relationship appears to be linear in
nature, which indicates that a delay to probiotic release does not change the nature of the
release itself; instead, it acts as a shift to the release. Upon linear regression, the R2
correlation coefficient was greater than 0.9 for each release amount, which further
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suggests a linear relationship between time to reach a given probiotic release checkpoint
and the corresponding delay.

Figure 4a-d: Probiotic Release Profiles with varying release rates. (a) Top left panel: Probiotic release profile with 6hour delay. (b) Top right panel: Probiotic release profile with 12-hour delay. (c) Bottom left panel: Probiotic release
profile with 24-hour delay. (d) Probiotic release profile with 48-hour delay. The release rates kR are as specified in the
legend, ranging from 5 × 10-2 at the lowest, 5 × 10-1 at an intermediate level for kR, and 1 at the highest.

Furthermore, altering release rate also shows impact on the probiotic release profile.
As the release rate kR decreases, the probiotics are expected to take a longer time to exit
the scaffold which is showcased in Figure 3.
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Figure 5a-d: Time to reach various probiotic release amounts (25%, 50%, 75%, and 95%) vs. corresponding release
rate kR. (a) Top left panel: Release checkpoint vs. kR with 6-hour delay. (b) Top right panel: Release checkpoint vs. kR
with 12-hour delay. (c) Bottom left panel: Release checkpoint vs. kR with 24-hour delay. (d) Top left panel: Release
checkpoint vs. kR with 48-hour delay.

It is important for the release rate to be distinguishable from the probiotic death due to
antibiotic death rate kAD since if the release rate is too high, it is difficult to attribute the
cause of rapid decay to either a high release rate or probiotic interaction with antibiotic.
For 1- and 2-day delays, the time to reach a given probiotic release checkpoint expectedly
decreases, albeit with diminishing returns. This relationship between time to reach a
given probiotic release checkpoint and release rate kR appears to follow a negative
logarithmic relationship. For the 6- and 12-hour delays, this trend does not persist
because, when the delay is set to such short lengths of time, the probiotic release is
subject to antibiotic interaction. As such, figures 4c and 4d are showing how antibiotic
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interaction affects the time to reach probiotic release checkpoints in addition to how the
release rate kR affects this time. From figures 4c and 4d, they show that despite antibiotic
interaction significantly impacting probiotic release, the release rate still causes
differences between the probiotic release, and this difference becomes compounded as
probiotics continue to release; hence why the 95% release checkpoints in figures 5c and
5d have more variance than the other release checkpoints.

4.2 Lactic Acid Release and pH Change
The initial condition of the system features a pH of 7 which is considered to be
indicative of BV.

Figure 6a-b: Lactic acid release with associated pH change over time. Note that the interior of the scaffold is modeled,
so lactic acid release indicates lactic acid released from the scaffold into the exterior environment. The release rate kR
was set to 5 × 10-1 h-1.

Elevated vaginal pH is a diagnostic indicator of BV; above 4.5 is considered elevated, a
pH of 5 would be a slight infection, pH of 6 would be a moderate infection, and pH of 7
would be highly infected [7][8][4]. As a diagnostic indicator, elevated vaginal pH is not
specific to BV, however it is one of the conditions in Amsel’s criteria, which is the most
common form of BV diagnosis [8]. A healthy vaginal pH is considered to be around pH 4
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[4]

so it is vital for probiotics to produce sufficient lactic acid to counteract the elevated

pH and maintain a healthy environment.

Based on the modeling results, the probiotics will cause a pH shift that is sensitive
to the infection level. If there is a high level of infection, the initial pH will begin at 7 and
decrease to 4. However, if there is a moderate level of infection, the initial pH will begin
at 6 and the probiotics cause a smaller shift in pH, resulting in the pH decreasing and
reaching equilibrium at 4. With a low level of infection, a smaller shift of pH is required
since the pH balance has not been disrupted as severely as with higher levels of infection.
In this scenario, pH starts at 5 and decreases to equilibrium at pH 4. The modeling results
indicate that regardless of initial pH, the probiotics will proliferate such that the lactic
acid equilibrium yields a pH of 4. Only the initial condition of pH 7 was shown since the
pH follows the same kinetics regardless of initial condition, where the lactic acid
equilibrium quickly results in an equilibrium pH of roughly 4. Additionally, lactic acid
release inside the scaffold as well as associated pH remain uniform across various delays
since probiotics continue to produce lactic acid regardless of release status. As a result,
the delay of probiotic release does not impact lactic acid production and by extension,
pH. The same holds true for the impact of release rate kR on lactic acid production and
pH; since release rate only alters release of probiotic, it has no bearing on the probiotic
before release occurs.

5. Conclusions
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The aim of this model was to simulate probiotic release patterns, pH change and
assess associated recurrence prevention, release of two agents without overlap, and
determine the ideal delay between probiotics and antibiotics. More broadly though, the
aim was also to develop a tool that can help guide in vitro, ex vivo, or in vivo testing of an
antibiotic-probiotic scaffold for treatment of BV and prevention of recurrent BV. The
model was successful in producing probiotic release curves that avoided interaction with
the antibiotic and based on the model output, a delay of at least 1 day was required, while
a 2-day delay was optimal. Additionally, by modeling the effect of probiotics on pH, the
probiotics showed sensitivity to varying levels of infection. With pH 7 serving as a severe
infection, pH 6 serving as a moderate infection, and pH 5 serving as a slight infection, the
simulated probiotics showed stronger or weaker responses based on the level of infection.
At a pH indicative of infection, stronger pH shift was caused by the probiotics while a pH
indicative of a weaker infection caused a smaller pH shift. More importantly, the
probiotics were able to restore pH to a healthy level (pH 4) and maintain equilibrium at
that pH. There still remain factors worth investigating, however. For instance, this model
uses the same geometry as the fiber described in Halwes et al., however, due to the nature
of 3D printing, a variety of geometries can be tested. While varying system geometry
would be valuable in and of itself, perhaps more valuable would be an expansion to the
model that allows for the simulation of BV infection. Currently, the model domain is
restricted to a single scaffold for the sake of practicality. This means that, since G.v. is
not loaded into scaffolds, G.v. are not being simulated and neither is the competition
between L.cr. and G.v. Due to the lack of G.v. simulation, BV infection as a whole is not
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being modeled; instead, only the release and proliferation of probiotics and key
components related thereof. As a result, efficacy of treatment and recurrence of BV are
difficult to predict from this model due to the fact that only the inside of the scaffold is
simulated, and recurrence depends on conditions outside the scaffold, in the FRT.

6. Recommendations
There still remain factors worth investigating, however. The first of these factors
would be the characterization of drug release. The current standard for bacterial vaginosis
is antibiotic treatment. Typically, metronidazole, clindamycin, or tinidazole are used for
BV treatment, and the release characteristics of these antibiotics should be explored so
that probiotic release can be altered accordingly. The current model uses drug diffusivity
for an antiviral drug, whose release is largely based on simple diffusion. As such, it
would be reasonable to extend this behavior to BV antibiotics and modifying the current
model to fit these antibiotics would entail adjusting the diffusivity term in the model
based on release characteristics of antibiotics from 3D-printed scaffolds. This would
require experimental results that show antibiotic release from scaffolds.

Furthermore, this model uses the same geometry as the fiber described in Halwes et
al.[9], however, due to the nature of 3D printing, a variety of geometries can be tested. For
instance, scaffolds can be printed in geometries resembling capsules, IVRs, etc. all with
varying diameters, thicknesses, lengths, or widths. For any given geometry, a variety of
dimensions can be modeled and tested.
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While varying system geometry would be valuable in and of itself, perhaps more
valuable would be an expansion to the model that allows for the simulation of BV
infection. Currently, the model domain is restricted to a single scaffold for the sake of
practicality. This means that, since G.v. is not loaded into scaffolds, G.v. are not being
simulated and neither is the competition between L.cr. and G.v. Due to the lack of G.v.
simulation, BV infection as a whole is not being modeled; instead, only the release and
proliferation of probiotics and key components related thereof. As a result, efficacy of
treatment and recurrence of BV are difficult to predict from this model due to the fact that
only the inside of the scaffold is simulated, and recurrence depends on conditions outside
the scaffold, in the FRT. Not only would infection become a possible simulation in this
model, but release could be more accurately modeled. Since the model only accounts for
the interior of the scaffold, the probiotic release from the scaffold into the environment is
modeled, but the proliferation of probiotics after being released is not modeled. With an
expansion to the model that would allow for an exterior environment to be simulated, the
probiotic release can take into account proliferation after release and be more comparable
to experimental data.
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